Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590548 | 0.79 | GAA (0.38) | CHRNA7KCNH2 | |
| SCHEMBL16757065 | 0.75 | KMT2A (0.36) | CHRNA7KCNH2 | |
| SCHEMBL8968088 | 0.75 | CHRNA7 (0.38) | CHRNA7KCNH2 | |
| SCHEMBL9561693 | 0.75 | CHRNA7 (0.34) | CHRNA7KCNH2 | |
| SCHEMBL10924907 | 0.75 | KCNH2 (0.33) | CHRNA7KCNH2 | |
| SCHEMBL25165704 | 0.72 | KMT2A (0.37) | KCNH2 | |
| SCHEMBL8265735 | 0.72 | KMT2A (0.37) | KCNH2 | |
| SCHEMBL30699749 | 0.72 | GAA (0.37) | — | |
| SCHEMBL10842235 | 0.71 | CHRNA7 (0.33) | CHRNA7KCNH2 | |
| SCHEMBL24637969 | 0.71 | KCNH2 (0.32) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0703233-A2 | Process for the preparation of 5-substituted-1-azabicyclo (3.3.0) octanes | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1996-03-27 | — | — | EP | claimed |
| JP-8041065-A | — | — | None | — | — | JP | disclosed |
| JP-6306075-A | — | — | None | — | — | JP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2022194191-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12D | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
| US-20080262031-A1 | 4-Aminoquinoline Derivatives as Antimalarials | CTG PHARMA S.R.L. (IT) | 2008-10-23 | — | — | US | disclosed |
| EP-1846401-B1 | NEW 4-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIALS | CTG PHARMA S R L (IT) | 2008-06-18 | — | — | EP | disclosed |
| EP-1846401-A1 | NEW 4-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIALS | CTG Pharma S.r.l. (IT) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082030-A1 | NEW 4-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIALS | CTG PHARMA S.R.L. (IT) | 2006-08-10 | — | — | WO | disclosed |
| US-5318977-A | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents | G. D. SEARLE & CO. (US) | 1994-06-07 | — | — | US | disclosed |
| US-5280028-A | Containing ketone structure in position2 | G. D. SEARLE & CO. (US) | 1994-01-18 | — | — | US | disclosed |
| WO-1994000454-A1 | BENZIMIDAZOLE COMPOUNDS | G.D. SEARLE & CO. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0543307-A2 | Nootropic agent | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-05-26 | — | — | EP | disclosed |
| EP-0528026-A1 | NEW MESO-AZACYCLIC AROMATIC ACID AMIDES AND ESTERS AS NOVEL SEROTONERGIC AGENTS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0504680-A1 | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992015590-A1 | NEW MESO-AZACYCLIC AROMATIC ACID AMIDES AND ESTERS AS NOVEL SEROTONERGIC AGENTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-4617401-A | ANTISPASMODIC AGENTS, VASODILATORS | SUNTORY LTD. (JP) | 1986-10-14 | — | — | US | disclosed |
| EP-0039903-B1 | 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1986-04-09 | — | — | EP | disclosed |
| EP-0039903-A2 | 8-Substituted pyrrolizidines and quaternary ammonium salts thereof | SUNTORY KABUSHIKI KAISHA (JP) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CHRNA7 4848/4885KCNH2 4373/4885 |
| US-20080262031-A1 | 4-Aminoquinoline Derivatives as Antimalarials | QTRT1, QTRT2, RECQL | CHRNA7 2751/4885KCNH2 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.